Reported about 1 month ago
Eli Lilly has emerged as a dominant player in the GLP-1 weight-loss drug market, thanks to its established products Wegovy and Zepbound, which have seen skyrocketing sales growth. Roundhill Investments CEO Dave Mazza highlights Eli Lilly's decades-long experience in this sector and its proactive approach in making Zepbound more accessible. In contrast, he expresses skepticism towards Hims & Hers Health, suggesting the trend towards quality, FDA-approved drugs like Eli Lilly’s will dominate as supply difficulties from competitors ease.
Source: YAHOO